End Stage Renal Disease Clinical Trial
Official title:
Norepinephrine Infusion Combined With Goal-directed Fluid Therapy Reduces Delayed Graft Function Incidence in Patients Undergoing Kidney Transplantations: a Randomized Multicenter Clinical Trial
Verified date | April 2024 |
Source | RenJi Hospital |
Contact | Diansan Su, Dr. |
Phone | +862168383702 |
diansansu[@]yahoo.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Delayed graft function (DGF), delineated by the necessity for dialytic intervention within the initial week post-transplantation, afflicts approximately 20%-50% of recipients. The primary objective of this study is to investigate the potential efficacy of norepinephrine infusion in conjunction with goal-directed fluid therapy (GDFT) in mitigating the occurrence of DGF among individuals undergoing kidney transplantations. The findings of this investigation have the potential to advance the field of perioperative care in kidney transplantations by providing insights into optimized management strategies.
Status | Recruiting |
Enrollment | 380 |
Est. completion date | June 30, 2026 |
Est. primary completion date | April 30, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Recipients aged 18 years or older 2. Scheduled to undergo kidney transplantations under general anesthesia 3. Cadaveric kidney transplantations 4. Sign the informed consent form Exclusion Criteria: 1. Donors aged under 18 years 2. Donor kidneys classified as Maastricht category I or II 3. Contraindications to radial artery catheterization 4. Pregnancy 5. Cardiac dysfunction (exercise tolerance less than 4 METS) 6. Severe liver dysfunction (Child Pugh C-grade) 7. Respiratory diseases with tidal volume intolerance exceeding 8ml/kg 8. Severe arrhythmias, including atrial fibrillation, frequent atrial or ventricular premature beats, moderate or severe aortic and mitral regurgitation 9. Double-kidney transplantations 10. Simultaneous organ or additional surgeries during kidney transplantations 11. Repeat kidney transplantations 12. Concurrent participation in other clinical trials 13. Patients deemed ineligible by researchers |
Country | Name | City | State |
---|---|---|---|
China | Renji Hospital | Shanghai | Shanghai |
China | General Hospital of Northern Theatre Command | Shenyang | Liaoning |
China | the First Affiliated Hospital of Zhengzhou University | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
RenJi Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The incidence of acute rejection during hospitalization | The incidence of acute rejection during hospitalization | Patients will be followed from surgery completion to discharge, an average of 20 days. | |
Other | The survival rates of transplanted kidneys at the one-year postoperative mark | The survival rates of transplanted kidneys at the one-year postoperative mark | Patients will be followed from surgery completion to one year after surgery. | |
Other | The survival rates of transplanted patients at the one-year postoperative mark | The survival rates of transplanted patients at the one-year postoperative mark | Patients will be followed from surgery completion to one year after surgery. | |
Other | The occurrence of adverse events (AEs) | The occurrence of adverse events (AEs) recorded by the common terminology criteria for adverse events (CTCAE) 5.0 | Patients will be followed from surgery completion to discharge, an average of 20 days. | |
Primary | The incidence of delayed graft function (DGF) | The need for dialytic intervention within the initial week post-transplantation | Patients will be followed from postoperative day 1 to 7. | |
Secondary | The area under the curve of serum creatinine levels from postoperative day 1 to 7 | The area under the curve of serum creatinine levels from postoperative day 1 to 7 | Patients will be followed from postoperative day 1 to 7. | |
Secondary | Duration of DGF | The interval from surgery completion to the last dialysis up to 84 days post-surgery | Patients will be followed from surgery completion to the last dialysis up to 84 days post-surgery. | |
Secondary | Number of dialysis sessions during postoperative hospitalization | Number of dialysis sessions during postoperative hospitalization | Patients will be followed from surgery completion to discharge,an average of 20 days. | |
Secondary | Total urine output on the second postoperative day | Total urine output on the second postoperative day | Patients will be followed on the second postoperative day. | |
Secondary | Duration of intensive care unit (ICU) stay | Duration of intensive care unit (ICU) stay | Patients will be followed during Intensive care unit (ICU) stay, an average of 2 days. | |
Secondary | Length of hospitalization | Length of hospitalization | Patients will be followed from hospitalization to discharge, an average of 20 days. | |
Secondary | Incidence of readmission within 30 days post-discharge | Incidence of readmission within 30 days post-discharge | Patients will be followed from discharge to 30 days after discharge. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04076488 -
Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases
|
N/A | |
Completed |
NCT03289650 -
Extended Release Tacrolimus vs. Twice-Daily Tacrolimus
|
Phase 3 | |
Completed |
NCT04042324 -
A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
|
Phase 1/Phase 2 | |
Completed |
NCT01242904 -
Use of a Bimodal Solution for Peritoneal Dialysis
|
Phase 2 | |
Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
Completed |
NCT03257410 -
Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A | |
Withdrawn |
NCT02130817 -
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
|
Phase 4 | |
Completed |
NCT05540457 -
Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)
|
N/A | |
Not yet recruiting |
NCT04900610 -
The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis
|
N/A | |
Recruiting |
NCT02176434 -
Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease
|
N/A | |
Active, not recruiting |
NCT02581449 -
Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis
|
Phase 2 | |
Completed |
NCT02215655 -
Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence
|
N/A | |
Completed |
NCT02830490 -
Reliability of Functional Measures in Hemodialysis Patient.
|
N/A | |
Completed |
NCT02832466 -
Quantifying the Deterioration of Physical Function in Renal Patients
|
N/A | |
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Completed |
NCT02832440 -
Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis
|
N/A | |
Recruiting |
NCT01912001 -
Virtual Ward for Home Dialysis
|
N/A |